Truist Financial Reaffirms Their Buy Rating on Tourmaline Bio (TRML)

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Tourmaline Bio (TRML – Research Report) today. The company’s shares opened today at $14.73.

According to TipRanks, Devarakonda is a 4-star analyst with an average return of 15.3% and a 53.01% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as Cytokinetics, Keros Therapeutics, and Edgewise Therapeutics.

Tourmaline Bio has an analyst consensus of Strong Buy, with a price target consensus of $56.80, a 285.61% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $48.00 price target.

The company has a one-year high of $48.31 and a one-year low of $9.18. Currently, Tourmaline Bio has an average volume of 436.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Tourmaline Bio (TRML) Company Description:

Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders.